UK approves Wegovy pill in major shift in obesity treatment options

Approval is based on results from the phase 3 OASIS 4 clinical trial

Wegovy pill smashes past 3mn prescriptions in under six months in US

The company said Wegovy hit its first one million prescriptions within 12 weeks of availability

NADMED Limited appoints James Lee as CEO to drive global expansion

Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation

EMA gives green light to warmer & simpler delivery rules for Wegovy injection

Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio

The Semaglutide Surge: How a diabetes therapy sparked India’s weight loss wave

As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact

Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData

Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning

Emcure Pharma reduces Poviztra starting dose price by 55% in India

The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country

New diabetes drug UBT251 shows strong phase 2 results in China

European Commission greenlights higher-dose Wegovy for obese adults

Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose

Wegovy pill marks first GLP-1 weight-loss medicine in oral form

The approval introduces a needle-free alternative to injectable GLP-1 therapies